⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TVTX News
Travere Therapeutics, Inc. Common Stock
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI ® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
businesswire.com
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
TVTX
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
businesswire.com
TVTX
American Kidney Fund’s UCKD Summit Helps Drive Early Recognition for Rare and Genetic Kidney Diseases
globenewswire.com
NVS
TVTX
VRTX
ALNY
NTRA
SNY
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
prnewswire.com
TVTX
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI ® (sparsentan) in Focal Segmental Glomerulosclerosis
businesswire.com
TVTX
Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019-2026 Now Available; Delivers 300-Page Deal Directory Covering 1,107 Companies and Contract-Level Financial Terms Since 2019
globenewswire.com
TVTX
NEXT
RLMD
VIVO
Form 8-K
sec.gov
TVTX
AMTX
BMRN
LNT
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
TVTX